Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome.

Dairkee SH, Nicolau M, Sayeed A, Champion S, Ji Y, Moore DH, Yong B, Meng Z, Jeffrey SS.

Oncogene. 2007 Sep 20;26(43):6269-79. Epub 2007 Apr 30.

PMID:
17471242
3.

Transduction of E2F-1 TAT fusion proteins represses expression of hTERT in primary ductal breast carcinoma cell lines.

Elliott KA, Rickords LF, Labrum JM.

Mol Cancer. 2008 Mar 26;7:28. doi: 10.1186/1476-4598-7-28.

4.

Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.

Privette LM, González ME, Ding L, Kleer CG, Petty EM.

Cancer Res. 2007 Jul 1;67(13):6064-74. Epub 2007 Jun 27.

5.

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215. Epub 2009 Jan 5.

6.

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.

Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV.

J Clin Oncol. 2008 Sep 1;26(25):4078-85. doi: 10.1200/JCO.2007.13.4429.

7.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
8.

Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.

Kok M, Koornstra RH, Margarido TC, Fles R, Armstrong NJ, Linn SC, Van't Veer LJ, Weigelt B.

J Pathol. 2009 Jul;218(3):316-26. doi: 10.1002/path.2544.

PMID:
19353633
9.

hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer.

Elkak A, Mokbel R, Wilson C, Jiang WG, Newbold RF, Mokbel K.

Anticancer Res. 2006 Nov-Dec;26(6C):4901-4.

10.

Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.

Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schütte J, Gardiner-Garden M, Ormandy CJ, McArthur G, Butt AJ, Sutherland RL.

PLoS One. 2008 Aug 20;3(8):e2987. doi: 10.1371/journal.pone.0002987.

11.

Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.

Herbert BS, Wright AC, Passons CM, Wright WE, Ali IU, Kopelovich L, Shay JW.

J Natl Cancer Inst. 2001 Jan 3;93(1):39-45.

12.

Early upregulation of cyclooxygenase-2 in human papillomavirus type 16 and telomerase-induced immortalization of human esophageal epithelial cells.

Zhuang ZH, Tsao SW, Deng W, Wang JD, Xia HH, He H, Feng HC, Wang LD, Gu Q, Lam SK, Lin MC, Kung HF, Wong BC.

J Gastroenterol Hepatol. 2008 Oct;23(10):1613-20. doi: 10.1111/j.1440-1746.2008.05509.x. Epub 2008 Aug 20.

PMID:
18717758
13.

Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells.

Nijjar T, Bassett E, Garbe J, Takenaka Y, Stampfer MR, Gilley D, Yaswen P.

Oncogene. 2005 May 5;24(20):3369-76.

PMID:
15735711
14.

Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2.

Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK.

Cancer Res. 2008 Jun 15;68(12):4580-7. doi: 10.1158/0008-5472.CAN-08-0316.

15.

Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E.

Mol Cancer. 2008 Nov 6;7:83. doi: 10.1186/1476-4598-7-83.

16.

The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.

Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG.

Int J Mol Med. 2007 Oct;20(4):605-11.

PMID:
17786294
17.

Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts.

Chisamore MJ, Wilkinson HA, Flores O, Chen JD.

Mol Cancer Ther. 2009 Mar;8(3):672-81. doi: 10.1158/1535-7163.MCT-08-1028. Epub 2009 Mar 10.

18.

Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer.

Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, Bajetta E, Celio L, Greco M, Fabbri A, Pierotti MA, Daidone MG.

Endocr Relat Cancer. 2008 Jun;15(2):439-49. doi: 10.1677/ERC-07-0274.

19.

Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers.

Smalley MJ, Iravani M, Leao M, Grigoriadis A, Kendrick H, Dexter T, Fenwick K, Regan JL, Britt K, McDonald S, Lord CJ, Mackay A, Ashworth A.

Breast Cancer Res. 2007;9(6):R85.

20.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk